microRNAs in Cancer: Lessons from melanoma

Current Pharmaceutical Design

Volumn 20, Issue 33, 2014, Pages 5246-5259

  Greenberg, Eyal ^a,b   Nemlich, Yael ^a   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Cell cycle; Drug resistance; Immune evasion; Invasion; Melanoma; microRNAs; Migration; Proliferation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ARGONAUTE PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLINE; FRAGILE X MENTAL RETARDATION PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 10B; MICRORNA 125B; MICRORNA 145; MICRORNA 146A; MICRORNA 149; MICRORNA 155; MICRORNA 17; MICRORNA 182; MICRORNA 18B; MICRORNA 193B; MICRORNA 195; MICRORNA 196A; MICRORNA 204; MICRORNA 214; MICRORNA 338; MICRORNA 432; MICRORNA 565; NAVITOCLAX; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IMMUNE EVASION; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR INVASION; GENETICS; METABOLISM;

HUMANS; MELANOMA; MICRORNAS;

EID: 84924887180     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140128210105     Document Type: Article

References (169)

1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81: 500-7.
2. Gloster HM, Jr., Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22: 217-26.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA: a cancer journal for clinicians 2013; 63: 11-30.
4. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. Journal of the National Cancer Institute 2013; 105: 175-201.
5. Surveillance epidemiology and End results. 2008. http://seer. cancer. gov/statfacts/html/melan. html#ref11. In: ed. National Cancer Insitute: Bethesda, MD 2012.
6. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. New Eng J Med 2003; 349: 2233-40.
7. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al.] 2006; 32: 481-92.
8. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
9. Udayakumar D, Mahato B, Gabree M, Tsao H. Genetic determinants of cutaneous melanoma predisposition. Seminars in cutaneous medicine and surgery 2010; 29: 190-5.
10. de Snoo FA, Kroon MW, Bergman W, et al. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. J Am Acad Dermatol 2007; 56: 748-52.
11. Clark WH, Jr., From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705-27.
12. Mihm MC, Jr., Clark WH, Jr., From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. New Eng J Med 1971; 284: 1078-82.
13. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26: 3445-55.
14. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-Update 2012. European journal of cancer 2012; 48: 2375-90.
15. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-7.
16. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5: 875-85.
17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
18. Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002; 8: 3728-33.
19. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogenactivated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63: 756-9.
20. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF-and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005; 36: 486-93.
21. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005; 170: 703-8.
22. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
23. Ma L, Weinberg RA. MicroRNAs in malignant progression. Cell Cycle 2008; 7: 570-2.
24. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 2004; 116: 281-97.
25. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004; 32: D109-11.
26. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34: D140-4.
27. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
28. Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005; 33: 2697-2706.
29. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
30. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-34.
31. Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3-UTR. Genes & Development 2004; 18: 132-7.
32. Lewis BP, Shih Ih, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of Mammalian MicroRNA Targets. Cell 2003; 115: 787-98.
33. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
34. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. The Lancet Oncology 2012; 13: e249-e258.
35. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
36. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
37. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene; 27: S52.
38. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
39. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol 2008; 18: 505-16.
40. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 2013; 15: 546-54.
41. Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010; 285: 22809-17.
42. Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010; 70: 1635-44.
43. Yu Z, Willmarth NE, Zhou J, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010; 107: 8231-6.
44. Creighton CJ, Fountain MD, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res; 70: 1906-15.
45. Zhang Y, Guo J, Li D, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol 2010; 27: 685-9.
46. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-46.
47. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010; 70: 5147-54.
48. Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L. Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32: 21.
49. Chang CC, Yang YJ, Li YJ, et al. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol 2013.
50. Kang HW, Wang F, Wei Q, et al. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett 2012; 586: 897-904.
51. Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012; 72: 908-16.
52. Hong L, Lai M, Chen M, et al. The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res 2010; 70: 8547-57.
53. Fan X, Liu Y, Jiang J, et al. miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin (Shanghai) 2010; 42: 318-24.
54. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-9.
55. Kanemaru H, Fukushima S, Yamashita J, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011; 61: 187-93.
56. Poliseno L, Haimovic A, Segura MF, et al. Histology-specific microRNA alterations in melanoma. J Invest Dermatol 2012; 132: 1860-8.
57. Friedman EB, Shang S, de Miera EV, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 2012; 10: 155.
58. Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W, Brauch H. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptorpositive breast cancer following tamoxifen treatment. European journal of cancer 2013.
59. Greenberg E, Besser MJ, Ben-Ami E, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers 2013.
60. Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011; 6: e25787.
61. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007; 7: 246-55.
62. Patino WD, Susa J. Epigenetics of cutaneous melanoma. Adv Dermatol 2008; 24: 59-70.
63. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007; 39: 673-7.
64. Yang Y, Li X, Yang Q, et al. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet. Cytogenet. 2010; 200: 127-33.
65. Caramuta S, Egyhazi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest Dermatol. 2010; 130: 2062-70.
66. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-41.
67. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
68. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-10.
69. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-6.
70. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
71. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009; 361: 1058-66.
72. Bueno R, De RA, Dong L, et al. Second generation sequencing of the mesothelioma tumor genome. PLoS. One. 2010; 5: e10612.
73. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. Genome Res. 2010; 20: 413-427.
74. Drobetsky EA, Grosovsky AJ, Glickman BW. The specificity of UV-induced mutations at an endogenous locus in mammalian cells. Proc. Natl. Acad. Sci. U. S. A 1987; 84: 9103-7.
75. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
76. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43: 442-6.
77. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008; 18: 549-57.
78. Chen J, Feilotter HE, Pare GC, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010; 176: 2520-9.
79. Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2013; 32: 1330-7.
80. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68: 2745-54.
81. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003; 22: 3087-91.
82. Noguchi S, Mori T, Hoshino Y, et al. Comparative study of antioncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci 2012; 74: 1-8.
83. Jin L, Hu WL, Jiang CC, et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA 2011; 108: 15840-5.
84. Dar AA, Majid S, Rittsteuer C, et al. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 2013; 105: 433-42.
85. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 2011; 286: 16606-14.
86. Alla V, Kowtharapu BS, Engelmann D, et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11: 3067-78.
87. Jiang L, Lv X, Li J, Li X, Li W, Li Y. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem 2012; 114: 582-8.
88. Satzger I, Mattern A, Kuettler U, et al. microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp Dermatol 2012; 21: 509-14.
89. Noguchi S, Mori T, Otsuka Y, et al. Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J Biol Chem 2012; 287: 11769-77.
90. Noguchi S, Kumazaki M, Yasui Y, Mori T, Yamada N, Akao Y. MicroRNA-203 Regulates Melanosome Transport and Tyrosinase Expression in Melanoma Cells by Targeting Kinesin Superfamily Protein 5b. J Invest Dermatol 2013.
91. Jiang CC, Croft A, Tseng HY, et al. Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene 2013.
92. Bhattacharya A, Schmitz U, Wolkenhauer O, Schonherr M, Raatz Y, Kunz M. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene 2013; 32: 3175-83.
93. Penna E, Orso F, Cimino D, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011; 30: 1990-2007.
94. Streicher KL, Zhu W, Lehmann KP, et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012; 31: 1558-70.
95. Levati L, Alvino E, Pagani E, et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol 2009; 35: 393-400.
96. Levati L, Pagani E, Romani S, et al. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 2011; 24: 538-50.
97. Felli N, Felicetti F, Lustri AM, et al. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One 2013; 8: e56824.
98. Goswami S, Tarapore RS, Teslaa JJ, Grinblat Y, Setaluri V, Spiegelman VS. MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinant-binding protein. J Biol Chem 2010; 285: 20532-40.
99. Mazar J, DeYoung K, Khaitan D, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 2010; 5: e13779.
100. Mazar J, DeBlasio D, Govindarajan SS, Zhang S, Perera RJ. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett 2011; 585: 2467-76.
101. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2013; 32: 2984-91.
102. Greenberg E, Hershkovitz L, Itzhaki O, et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 2011; 6: e18936.
103. Couts KL, Anderson EM, Gross MM, Sullivan K, Ahn NG. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene 2013; 32: 1959-70.
104. Liu S, Kumar SM, Lu H, et al. MicroRNA-9 up-regulates Ecadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol 2012; 226: 61-72.
105. Luo C, Tetteh PW, Merz PR, et al. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 2013; 133: 768-75.
106. Nemlich Y, Greenberg E, Ortenberg R, et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest 2013; 123: 2703-18.
107. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
108. Segura MF, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009; 106: 1814-9.
109. Boyle GM, Woods SL, Bonazzi VF, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 2011; 24: 525-37.
110. Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 2010; 40: 841-9.
111. Bell RE, Khaled M, Netanely D, et al. Transcription Factor/microRNA Axis Blocks Melanoma Invasion Program by miR-211 Targeting NUAK1. J Invest Dermatol 2013.
112. Gaziel-Sovran A, Segura MF, Di Micco R, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011; 20: 104-18.
113. Karst AM, Gao K, Nelson CC, Li G. Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 2009; 124: 494-501.
114. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002; 109: 857-62.
115. Migliore C, Petrelli A, Ghiso E, et al. MicroRNAs impair METmediated invasive growth. Cancer Res 2008; 68: 10128-36.
116. Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X. Loss of microRNA-205 expression is associated with melanoma progression. Lab Invest 2012; 92: 1084-96.
117. Zehavi L, Avraham R, Barzilai A, et al. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer 2012; 11: 44.
118. Capoluongo E. Insulin-like growth factor system and sporadic malignant melanoma. Am J Pathol 2011; 178: 26-31.
119. Pencheva N, Tran H, Buss C, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell 2012; 151: 1068-82.
120. Mongaret C, Alexandre J, Thomas-Schoemann A, et al. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. International journal of cancer. J Int Cancer 2011; 129: 791-8.
121. Ohashi S, Natsuizaka M, Nakagawa H. MMP7 and activation of IGF-1R: a new insight into anti-EGFR therapeutic resistance in metastatic colorectal cancer. Cancer Biol Therapy 2011; 11: 184-7.
122. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO Journal 1998; 17: 7260-72.
123. Kivisaari AK, Kallajoki M, Ala-aho R, et al. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol 2010; 163: 726-35.
124. Toki F, Nanba D, Matsuura N, Higashiyama S. Ectodomain shedding of membrane-anchored heparin-binding EGF like growth factor and subcellular localization of the C-terminal fragment in the cell cycle. J Cellular Physiol 2005; 202: 839-48.
125. Giles KM, Brown RA, Epis MR, Kalinowski FC, Leedman PJ. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun 2013; 430: 706-10.
126. Curmi PA, Gavet O, Charbaut E, et al. Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell structure and function 1999; 24: 345-57.
127. Muller DW, Bosserhoff AK. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008; 27: 6698-706.
128. Braig S, Mueller DW, Rothhammer T, Bosserhoff AK. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci 2010; 67: 3535-48.
129. Mueller DW, Bosserhoff AK. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer 2011; 129: 1064-74.
130. Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One 2010; 5.
131. Mazar J, Khaitan D, DeBlasio D, et al. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One 2011; 6: e24922.
132. Asangani IA, Harms PW, Dodson L, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012; 3: 1011-25.
133. Hwang SJ, Seol HJ, Park YM, et al. MicroRNA-146a suppresses metastatic activity in brain metastasis. Mol Cells 2012; 34: 329-34.
134. Dynoodt P, Speeckaert R, De Wever O, et al. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol 2013; 42: 1443-51.
135. Noman MZ, Buart S, Romero P, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72: 4629-41.
136. Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012; 72: 460-71.
137. Segura MF, Belitskaya-Levy I, Rose AE, et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res 2010; 16: 1577-86.
138. Satzger I, Mattern A, Kuettler U, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010; 126: 2553-62.
139. Leidinger P, Keller A, Borries A, et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010; 10: 262.
140. Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumorrelated genes and disease outcome in cutaneous melanoma. Epigenetics 2011; 6: 388-94.
141. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694.
142. Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008; 54: 482-90.
143. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
144. Saldanha G, Potter L, Shendge P, et al. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. J Invest Dermatol 2013; 133: 1381-4.
145. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-37.
146. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-15.
147. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
148. Liu S, Tetzlaff MT, Cui R, Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol 2012; 181: 1823-35.
149. Das SK, Sokhi UK, Bhutia SK, et al. Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells. Proc Natl Acad Sci USA 2010; 107: 11948-53.
150. Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol Cancer Ther 2010; 9: 2943-50.
151. Chen J, Zhang X, Lentz C, et al. miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol 2011; 179: 2162-8.
152. Glud M, Rossing M, Hother C, et al. Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res 2010; 20: 479-84.
153. Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008; 68: 1362-8.
154. Haflidadottir BS, Bergsteinsdottir K, Praetorius C, Steingrimsson E. miR-148 regulates Mitf in melanoma cells. PLoS One 2010; 5: e11574.
155. Deng Y, Deng H, Bi F, et al. MicroRNA-137 targets carboxylterminal binding protein 1 in melanoma cell lines. Int J Biol Sci 2011; 7: 133-7.
156. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219: 214-21.
157. Jukic DM, Rao UN, Kelly L, et al. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010; 8: 27.
158. Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010; 70: 4163-73.
159. Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012; 106: 553-61.
160. Noguchi S, Mori T, Hoshino Y, Yamada N, Maruo K, Akao Y. MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas. Vet Comp Oncol 2013; 11: 113-23.
161. Grignol V, Fairchild ET, Zimmerer JM, et al. miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br J Cancer 2011; 105: 1023-9.
162. Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM. MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 2011; 286: 39172-8.
163. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009; 379: 790-4.
164. Mattia G, Errico MC, Felicetti F, et al. Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res 2011; 24: 953-65.
165. Reuland SN, Smith SM, Bemis LT, et al. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol 2013; 133: 1286-93.
166. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009; 129: 1740-51.
167. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009; 15: 2988-94.
168. Wang HF, Chen H, Ma MW, et al. miR-573 regulates melanoma progression by targeting the melanoma cell adhesion molecule. Oncol Rep 2013; 30: 520-6.
169. Liu N, Sun Q, Chen J, et al. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kappaB1 pathway. Oncol Rep 2012; 28: 961-8.